By comparing between the responders and non-responders of the PD-1-based therapy, the intestinal bacterium most significantly associated with beneficial therapeutic responses in both NSCLC and RCC patients was Akkermansia muciniphila [66]. Here, PDCD1 is linked to non-small cell lung carcinoma.